<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185883</url>
  </required_header>
  <id_info>
    <org_study_id>20190135</org_study_id>
    <nct_id>NCT04185883</nct_id>
  </id_info>
  <brief_title>Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)</brief_title>
  <official_title>A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of sotorasib administered in investigational regimens&#xD;
      in adult participants with KRAS p.G12C mutant advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Anticipated">January 3, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 12, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants with Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants with Treatment-related Adverse Events</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants with Clinically Significant Changes in Vital Signs</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants with Clinically Significant Changes in ECG Measurements</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants with Clinically Significant Changes in Laboratory Test Values</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Objective Response Rate</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Area Under the Plasma Concentration-time Curve (AUC)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Objective Response Rate</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Disease Control Rate</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Duration of Response</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Progression-free Survival</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Duration of Stable Disease</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Time to Response</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Overall Survival</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib + EGFR Inhibitor +/- Chemotherapeutic Regimen Only: Quantification of Plasma Levels</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib Monotherapy Only: Intracranial Objective Response Rate</measure>
    <time_frame>12 Months</time_frame>
    <description>Intracranial objective response rate assessed per Response Assessment in Neuro-oncology Brain Metastases (RANO-BM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib Monotherapy Only: Intracranial Disease Control Rate</measure>
    <time_frame>12 Months</time_frame>
    <description>Intracranial disease control rate assessed per Response Assessment in Neuro-oncology Brain Metastases (RANO-BM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib Monotherapy Only: Intracranial Duration of Response</measure>
    <time_frame>12 Months</time_frame>
    <description>Intracranial duration of response assessed per Response Assessment in Neuro-oncology Brain Metastases (RANO-BM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib Monotherapy Only: Time to Intracranial Radiation Therapy</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib Monotherapy Only: Intracranial Progression-free Survival (PFS)</measure>
    <time_frame>12 Months</time_frame>
    <description>Intracranial PFS assessed per Response Assessment in Neuro-oncology Brain Metastases (RANO-BM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib Monotherapy Only: Non-intracranial Progression-free Survival (PFS)</measure>
    <time_frame>12 Months</time_frame>
    <description>Non-intracranial PFS assessed per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib Monotherapy Only: Overall Progression-free Survival (PFS)</measure>
    <time_frame>12 Months</time_frame>
    <description>Overall PFS assessed per RECIST 1.1 and RANO-BM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib + TNO155 Only: Best Overall Response</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Number of Participants with Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Number of Participants with Grade â‰¥3 Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Area Under the Plasma Concentration-time Curve (AUC)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Disease Control Rate</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Duration of Response</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Progression-free Survival</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Time to Response</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Overall Survival</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib + Afatinib + Loperamide Only: Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib + Afatinib + Loperamide Only: Number of Participants with Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib + Afatinib + Loperamide Only: Number of Participants with Treatment-related Adverse Events</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib + Afatinib + Loperamide Only: Number of Participants with Clinically Significant Changes in Vital Signs</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib + Afatinib + Loperamide Only: Number of Participants with Clinically Significant Changes in ECG Measurements</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Sotorasib + Afatinib + Loperamide Only: Number of Participants with Clinically Significant Changes in Laboratory Test Values</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">1273</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Kirsten Rat Sarcoma (KRAS) pG12C Mutation</condition>
  <arm_group>
    <arm_group_label>Sotorasib + trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Sotorasib + trametinib Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib + AMG 404</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Sotorasib + AMG 404 Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib + RMC-4630</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Sotorasib + RMC-4630 Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants, with KRAS p.G12C mutant advanced solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib + afatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental:Sotorasib + afatinib Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced non-small cell lung cancer.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Sotorasib + pembrolizumab Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib + panitumumab +/- FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Sotorasib + panitumumab +/- FOLFIRI Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib + atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sotorasib + atezolizumab Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib + carboplatin, pemetraxed, docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Sotorasib + carboplatin, pemetraxed, docetaxel Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Sotorasib only Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer with brain metastases.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer with brain metastases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib + palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Sotorasib + palbociclib Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib + everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Sotorasib + everolimus Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib + trametinib+ panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Sotorasib + trametinib+ panitumumab Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS P.G12C mutant advanced colorectal cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib + MVASIÂ® (bevacizumab-awwb)+ FOLFIRI or FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Sotorasib + MVASIÂ® (bevacizumab-awwb)+ FOLFIRI or FOLFOX Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced colorectal cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib + TNO155</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Exploration and Dose Expansion&#xD;
Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.&#xD;
Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotorasib + afatinib + loperamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Expansion&#xD;
â€¢ Upon completing the dose exploration part of the study with sotorasib + afatinib, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer, who will receive sotorasib + afatinib + loperamide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotorasib</intervention_name>
    <description>Sotorasib administered orally as a tablet.</description>
    <arm_group_label>Sotorasib + AMG 404</arm_group_label>
    <arm_group_label>Sotorasib + MVASIÂ® (bevacizumab-awwb)+ FOLFIRI or FOLFOX</arm_group_label>
    <arm_group_label>Sotorasib + RMC-4630</arm_group_label>
    <arm_group_label>Sotorasib + TNO155</arm_group_label>
    <arm_group_label>Sotorasib + afatinib</arm_group_label>
    <arm_group_label>Sotorasib + afatinib + loperamide</arm_group_label>
    <arm_group_label>Sotorasib + atezolizumab</arm_group_label>
    <arm_group_label>Sotorasib + carboplatin, pemetraxed, docetaxel</arm_group_label>
    <arm_group_label>Sotorasib + everolimus</arm_group_label>
    <arm_group_label>Sotorasib + palbociclib</arm_group_label>
    <arm_group_label>Sotorasib + panitumumab +/- FOLFIRI</arm_group_label>
    <arm_group_label>Sotorasib + pembrolizumab</arm_group_label>
    <arm_group_label>Sotorasib + trametinib</arm_group_label>
    <arm_group_label>Sotorasib + trametinib+ panitumumab</arm_group_label>
    <arm_group_label>Sotorasib Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 404</intervention_name>
    <description>AMG 404 administered as an intravenous (IV) infusion.</description>
    <arm_group_label>Sotorasib + AMG 404</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trametinib</intervention_name>
    <description>trametinib administered orally as a tablet.</description>
    <arm_group_label>Sotorasib + trametinib</arm_group_label>
    <arm_group_label>Sotorasib + trametinib+ panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RMC-4630</intervention_name>
    <description>RMC-4630 administered orally as a capsule.</description>
    <arm_group_label>Sotorasib + RMC-4630</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>afatinib</intervention_name>
    <description>afatinib administered orally as a tablet.</description>
    <arm_group_label>Sotorasib + afatinib</arm_group_label>
    <arm_group_label>Sotorasib + afatinib + loperamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>pembrolizumab administered as an intravenous (IV) infusion.</description>
    <arm_group_label>Sotorasib + pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>panitumumab</intervention_name>
    <description>panitumumab administered as an intravenous (IV) infusion.</description>
    <arm_group_label>Sotorasib + panitumumab +/- FOLFIRI</arm_group_label>
    <arm_group_label>Sotorasib + trametinib+ panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin, pemetrexed, docetaxel</intervention_name>
    <description>carboplatin, pemetrexed, docetaxel administered as an intravenous (IV) infusion.</description>
    <arm_group_label>Sotorasib + MVASIÂ® (bevacizumab-awwb)+ FOLFIRI or FOLFOX</arm_group_label>
    <arm_group_label>Sotorasib + carboplatin, pemetraxed, docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atezolizumab</intervention_name>
    <description>atezolizumab administered as an intravenous (IV) injection.</description>
    <arm_group_label>Sotorasib + atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>everolimus administered orally.</description>
    <arm_group_label>Sotorasib + everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palbociclib</intervention_name>
    <description>palbociclib administered orally as a tablet.</description>
    <arm_group_label>Sotorasib + palbociclib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVASIÂ® (bevacizumab-awwb)</intervention_name>
    <description>MVASIÂ® (bevacizumab-awwb) administered as an intravenous (IV) infusion.</description>
    <arm_group_label>Sotorasib + MVASIÂ® (bevacizumab-awwb)+ FOLFIRI or FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNO155</intervention_name>
    <description>TNO155 administered orally as a capsule.</description>
    <arm_group_label>Sotorasib + TNO155</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>FOLFIRI chemotherapy combination of leucovorin administered as an intravenous (IV) injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and irinotecan administered as IV injection.</description>
    <arm_group_label>Sotorasib + MVASIÂ® (bevacizumab-awwb)+ FOLFIRI or FOLFOX</arm_group_label>
    <arm_group_label>Sotorasib + panitumumab +/- FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX</intervention_name>
    <description>FOLFOX chemotherapy combination of leucovorin administered as intravenous (IV) injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and oxaliplatin administered as IV injection.</description>
    <arm_group_label>Sotorasib + MVASIÂ® (bevacizumab-awwb)+ FOLFIRI or FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loperamide</intervention_name>
    <description>Loperamide administered orally as a capsule.</description>
    <arm_group_label>Sotorasib + afatinib + loperamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women greater than or equal to 18 years old.&#xD;
&#xD;
          -  Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C&#xD;
             mutation identified through molecular testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary brain tumor.&#xD;
&#xD;
          -  Spinal cord compression, or untreated, or symptomatic, or active brain metastases, or&#xD;
             leptomeningeal disease from non-brain tumors.&#xD;
&#xD;
          -  Myocardial infarction within 6 months of study day 1.&#xD;
&#xD;
          -  Gastrointestinal (GI) tract disease causing the inability to take oral medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates Professional Corporation</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Cancer Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Southern California, Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers Denver Midtown</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30332</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Cancer Pavillion</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gibbs Cancer Center and Research Institute - Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Joyce Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>United States Oncology Regulatory Affairs Corporate Office</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>US Oncology Research Investigational Products Center</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists - Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Afatinib</mesh_term>
    <mesh_term>Loperamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

